Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CTPS1 | P17812 | 3/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.44 |
| ▸ | MTTP | P55157 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | APOB | P04114 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789887 | 0.89 | LMNA (0.58) | LMNAHTTCTPS1PDE5AMTTP | |
| SCHEMBL6796213 | 0.87 | CTPS1 (0.49) | LMNAHTTCTPS1PDE5AMEN1 | |
| SCHEMBL6795713 | 0.87 | CTPS1 (0.49) | CTPS1PDE5AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6793434 | 0.85 | LMNA (0.60) | LMNAHTTMTTPMEN1KMT2A | |
| SCHEMBL6794206 | 0.85 | LMNA (0.60) | LMNAHTTMTTPMEN1KMT2A | |
| SCHEMBL6800495 | 0.82 | MTTP (0.47) | LMNAMTTPSMOAPOBKDM4E | |
| SCHEMBL6795383 | 0.80 | LMNA (0.52) | LMNAHTTMTTPPTGS1SMN1; SMN2 | |
| SCHEMBL6792281 | 0.78 | SMO (0.62) | LMNAHTTMTTPPTGS1SMN1; SMN2 | |
| SCHEMBL7079804 | 0.78 | CTPS1 (0.50) | LMNAHTTCTPS1PDE5AMEN1 | |
| SCHEMBL6787209 | 0.78 | PTGS1 (0.51) | LMNAHTTMTTPPTGS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | LMNA 1239/4885HTT 2566/4885CTPS1 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.